CLYM
NASDAQ · Biotechnology
Climb Bio Inc
$6.78
+0.10 (+1.50%)
Open$6.84
Previous Close$6.68
Day High$6.99
Day Low$6.64
52W High$8.04
52W Low$1.05
Volume—
Avg Volume504.8K
Market Cap333.42M
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+285.1% upside
Current
$6.78
$6.78
Target
$26.11
$26.11
$17.52
$26.11 avg
$31.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 93.03M | 87.17M | 93.25M |
| Net Income | -25,402,018 | -21,372,578 | -19,024,947 |
| Profit Margin | -27.3% | -24.5% | -20.4% |
| EBITDA | -33,224,495 | -30,585,289 | -30,503,356 |
| Free Cash Flow | -14,578,727 | -14,999,377 | -17,296,703 |
| Rev Growth | -8.3% | +13.0% | +19.4% |
| Debt/Equity | 0.78 | 0.63 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |